<code id='B9D5FEC12B'></code><style id='B9D5FEC12B'></style>
    • <acronym id='B9D5FEC12B'></acronym>
      <center id='B9D5FEC12B'><center id='B9D5FEC12B'><tfoot id='B9D5FEC12B'></tfoot></center><abbr id='B9D5FEC12B'><dir id='B9D5FEC12B'><tfoot id='B9D5FEC12B'></tfoot><noframes id='B9D5FEC12B'>

    • <optgroup id='B9D5FEC12B'><strike id='B9D5FEC12B'><sup id='B9D5FEC12B'></sup></strike><code id='B9D5FEC12B'></code></optgroup>
        1. <b id='B9D5FEC12B'><label id='B9D5FEC12B'><select id='B9D5FEC12B'><dt id='B9D5FEC12B'><span id='B9D5FEC12B'></span></dt></select></label></b><u id='B9D5FEC12B'></u>
          <i id='B9D5FEC12B'><strike id='B9D5FEC12B'><tt id='B9D5FEC12B'><pre id='B9D5FEC12B'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:comprehensive    Page View:58467
          The FDA building -- First Opinion coverage from STAT
          Adobe

          WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

          Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

          advertisement

          To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          Teach medical students about patients with intellectual disabilities
          Teach medical students about patients with intellectual disabilities

          AdobeOliverMcGowanwas18yearsoldwhenhewashospitalizedinEnglandwithrecurrentseizuresandpneumonia.Hewas

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Supreme Court wrestles with OxyContin maker's bankruptcy deal

          STEFANIREYNOLDS/AFPviaGettyImagesWASHINGTON—TheSupremeCourtonMondaywrestledwithanationwidesettlement